Iterum Therapeutics Stock (NASDAQ:ITRM)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$0.27

52W Range

$0.25 - $1.56

50D Avg

$0.35

200D Avg

$0.68

Market Cap

$13.54M

Avg Vol (3M)

$834.94K

Beta

2.94

Div Yield

-

ITRM Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

9

IPO Date

May 25, 2018

Website

ITRM Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Sep 25
Operating Segments	$390.00K

Fiscal year ends in Dec 24 | Currency in USD

ITRM Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-18.70M	$-47.47M	$-30.38M
Net Income	$-24.77M	$-38.37M	$-44.43M
EBITDA	$-18.70M	$-34.58M	$-39.97M
Basic EPS	$-1.26	$-2.96	$-3.63
Diluted EPS	$-1.26	$-2.96	$-3.63

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 14, 25 | 8:30 AM

Q2 25Aug 05, 25 | 8:30 AM

Q1 25May 13, 25 | 8:30 AM

Peer Comparison

Ticker	Company
PLUR	Pluri Inc.
INTS	Intensity Therapeutics, Inc.
IBIO	iBio, Inc.
TAOX	TAO Synergies Inc.
RLYB	Rallybio Corporation
KLTO	Klotho Neurosciences, Inc.
QTTB	Q32 Bio Inc.
BOLD	Boundless Bio, Inc.
SONN	Sonnet BioTherapeutics Holdings, Inc.
ANTX	AN2 Therapeutics, Inc.